ADC Biotechnology Overview

  • Year Founded
  • 2010

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 62

Employees

  • Latest Deal Type
  • M&A

ADC Biotechnology General Information

Description

Developer of new conjugation technologies designed to offer new antibody-drug conjugates. The company has developed a patented Lock-Release technology for the development and manufacture of the Antibody Drug Conjugates (ADC) group of cancer therapies which are designed to specifically target and kill tumor cells and also offer bioconjugation services, enabling physicians to treat patients with antibody-drug conjugate and anti-cancer therapies.

Contact Information

Website
www.adcbio.com
Formerly Known As
Reaxa Biotech
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 4 Friarsgate
  • Whitefriars
  • Chester CH1 1XG
  • England, United Kingdom
Primary Industry
Discovery Tools (Healthcare)
Vertical(s)
Corporate Office
  • 4 Friarsgate
  • Whitefriars
  • Chester CH1 1XG
  • England, United Kingdom

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ADC Biotechnology Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
13. Merger/Acquisition 06-Apr-2021 Completed Generating Revenue
12. Later Stage VC 27-Mar-2020 Completed Generating Revenue
11. Later Stage VC 17-Jan-2020 Completed Generating Revenue
10. Later Stage VC (Series D) 14-Dec-2018 Completed Generating Revenue
9. Later Stage VC 20-Apr-2018 Completed Generating Revenue
8. Debt - General 19-Oct-2017 Completed Generating Revenue
7. Grant 25-Sep-2017 Completed Generating Revenue
6. Later Stage VC 21-Sep-2017 Completed Generating Revenue
5. Later Stage VC 01-Dec-2016 $249K $2M Completed Generating Revenue
4. Early Stage VC 20-Dec-2012 $1.11M $1.75M Completed Generating Revenue
To view ADC Biotechnology’s complete valuation and funding history, request access »

ADC Biotechnology Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
C Ordinary
C Ordinary
C Ordinary
C Ordinary
A Ordinary
B Ordinary
C Ordinary
C Ordinary
C Ordinary 35,765,056 $0.000012 $0.23 $0.23 1x $0.23 16.62%
D Ordinary 5,436,000 $0.000012 $0.23 $0.23 1x $0.23 2.53%
To view ADC Biotechnology’s complete cap table history, request access »

ADC Biotechnology Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of new conjugation technologies designed to offer new antibody-drug conjugates. The company has developed a pa
Discovery Tools (Healthcare)
Chester, United Kingdom
62 As of 2025

San Diego, CA
 

Emeryville, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

ADC Biotechnology Competitors (49)

One of ADC Biotechnology’s 49 competitors is BioLegend, a Formerly Accelerator/Incubator backed company based in San Diego, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
BioLegend Formerly Accelerator/Incubator backed San Diego, CA
Eureka Therapeutics Venture Capital-Backed Emeryville, CA
Oxford Biotherapeutics Private Equity-Backed Oxford, United Kingdom
Macrogenics Formerly VC-backed Rockville, MD
Gradalis Private Equity-Backed Carrollton, TX
You’re viewing 5 of 49 competitors. Get the full list »

ADC Biotechnology Patents

ADC Biotechnology Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-201617421-D0 Medical device comprising derivatised support Inactive 14-Oct-2016
GB-201518234-D0 Medical device comprising derivatised support Inactive 15-Oct-2015
JP-2017537975-A Adcs synthesis method using affinity resin Inactive 28-Oct-2014
GB-201419185-D0 Method of synthesising adcs using affinity resin Inactive 28-Oct-2014
CA-2965891-A1 Method of synthesising adcs using affinity resins Inactive 28-Oct-2014 C07K1/042
To view ADC Biotechnology’s complete patent history, request access »

ADC Biotechnology Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ADC Biotechnology Former Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds
Bioscience Managers Venture Capital Minority
Denbighshire County Council Government
Development Bank of Wales Growth/Expansion Minority
Downing Asset Manager Minority
Downing Ventures Venture Capital Minority
You’re viewing 5 of 8 investors. Get the full list »

ADC Biotechnology FAQs

  • When was ADC Biotechnology founded?

    ADC Biotechnology was founded in 2010.

  • Where is ADC Biotechnology headquartered?

    ADC Biotechnology is headquartered in Chester, United Kingdom.

  • What is the size of ADC Biotechnology?

    ADC Biotechnology has 62 total employees.

  • What industry is ADC Biotechnology in?

    ADC Biotechnology’s primary industry is Discovery Tools (Healthcare).

  • Is ADC Biotechnology a private or public company?

    ADC Biotechnology is a Private company.

  • What is ADC Biotechnology’s current revenue?

    The current revenue for ADC Biotechnology is .

  • How much funding has ADC Biotechnology raised over time?

    ADC Biotechnology has raised $25.2M.

  • Who are ADC Biotechnology’s investors?

    Bioscience Managers, Denbighshire County Council, Development Bank of Wales, Downing, and Downing Ventures are 5 of 8 investors who have invested in ADC Biotechnology.

  • Who are ADC Biotechnology’s competitors?

    BioLegend, Eureka Therapeutics, Oxford Biotherapeutics, Macrogenics, and Gradalis are some of the 49 competitors of ADC Biotechnology.

  • When was ADC Biotechnology acquired?

    ADC Biotechnology was acquired on 06-Apr-2021.

  • Who acquired ADC Biotechnology?

    ADC Biotechnology was acquired by Sterling Pharma Solutions.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process